Sharemaestro Newsreel

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH)

Monteverde & Associates PC, a class action law firm, has announced an investigation into Lantheus Holdings, Inc. (NASDAQ: LNTH) following its proposed sale to Curium US Holdings LLC. Shareholders are set to receive $102.50 per share in cash, plus potential contingent value rights of …

Organigram Global (TSX:OGI) Refreshes Cannabis Stocks Focus Across Markets

This article focuses on Organigram Global (TSX:OGI) and its position within the Canadian cannabis sector. It highlights a review that compares four leading companies—Organigram Global, SNDL, Village Farms International, and Auxly Cannabis Group—based on liquidity, operational discipline, capital allocation, and brand development. Organigram Global …

Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form Supernus, Inc., a new CNS-focused pharmaceutical company. The combined entity will have a portfolio of 11 commercialized products across addiction, ADHD, depression, and Parkinson's disease, with nearly $2.2 billion in revenue. …

Teva Pharmaceutical (NYSE: TEVA) insider plans Rule 144 sale of 12,827 shares

An insider at Teva Pharmaceutical Industries Limited (NYSE: TEVA) has filed a Rule 144 notice to sell 12,827 ordinary shares, valued at approximately $447,350.60. The sale, expected around August 3, 2026, stems from a Restricted Share Unit Award that vested on August 1, 2024, …

Teva Pharmaceutical (NYSE: TEVA) holder plans $892K sale of ordinary shares

A holder of Teva Pharmaceutical Industries Limited (NYSE: TEVA) plans to sell 25,578 ordinary shares, valued at approximately $892,050.65, through Citigroup Global Markets, Inc. The sale is scheduled to occur on or after August 3, 2026, and relates to a Restricted Share Unit Award …

Canaccord raises Neurocrine Bio price target on strong sales beat

Canaccord Genuity increased its price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX) from $200 to $210, maintaining a Buy rating, following the company's strong second-quarter performance. Neurocrine's sales for Ingrezza and Crenessity significantly exceeded analyst estimates, contributing to a 34% revenue growth. The company …

CNS-focused Supernus and Indivior agree merger terms

Supernus Pharma and Indivior have agreed to an all-stock merger, forming a new company, Supernus Inc., focused on CNS diseases with combined revenues of around $2.2 billion. The deal, expected to close in Q4, will see Indivior shareholders owning 56.5% of the new company …

Rockville's Supernus more than tripling size through merger of equals

Rockville's Supernus Pharmaceuticals is merging with Richmond-based Indivior in a "merger of equals" transaction. The combined company will be led by current Supernus CEO Jack Khattar and is expected to generate approximately $2.2 billion in annual revenue from nearly a dozen neurological and psychiatric …

Lantheus Stock Is Gaining Monday: What's Going On? - Lantheus Holdings (NASDAQ:LNTH)

Global investment firm CapVest Partners' portfolio company Curium is set to acquire Lantheus Holdings (NASDAQ:LNTH) in a deal valued at up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash, plus contingent value rights potentially adding $12.00 per share, totaling up …

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

Faruqi & Faruqi, LLP is investigating potential securities claims against Lifecore Biomedical, Inc. (NASDAQ: LFCR) on behalf of investors who suffered losses exceeding $75,000 between October 7, 2020, and March 19, 2024. The investigation stems from allegations that Lifecore made false or misleading statements …

Tilray Brands Inc. stock rises Monday, outperforms market

Tilray Brands Inc. (TLRY) stock rose 2.20% on Monday, closing at $4.64. This performance outpaced the broader market, with the NASDAQ Composite Index gaining 2.13% and the Dow Jones Industrial Average rising 1.32%. This marks the stock's third consecutive day of gains.

Perrigo Co. PLC stock outperforms competitors on strong trading day

Perrigo Co. PLC (PRGO) saw its stock rise by 5.64% to $10.68 on Monday, outperforming the broader market, which also experienced a strong trading session. This increase broke a two-day losing streak for the company's shares. The S&P 500 Index and Dow Jones Industrial …

Supernus, Indivior merge to beef up brain drug portfolio

Brain drug developers Supernus and Indivior have announced a merger aimed at combining their portfolios of neurological drugs. The new entity, to be called Supernus, will have a combined revenue of $2 billion (2025 figures) and aims to achieve annual cost reductions of $125 …

Hims & Hers Health stock may move 14% on Aug. 10 earnings

Hims & Hers Health Inc. Class A shares are projected to move 14% on August 10 when the company reports earnings, according to options data. Historically, the stock's actual movement has often differed from options-implied moves, sometimes falling significantly even when options suggested a …

Supernus Q2 Falls To Loss, Despite 32% Revenue Jump; To Merge With Indivior In All-Stock Deal

(RTTNews) - Supernus Pharmaceuticals Inc. (SUPN) Monday reported a slip to loss in the second quarter, on one-time impairment charges, interest expense and a reversal of income tax benefit to an expense, despite a 32% increase in revenue, compared to the prior year. The …

Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential breaches of fiduciary duty related to its transaction with Indivior Pharmaceuticals. Supernus shareholders are set to receive 1.5401 common shares of Indivior for each Supernus share, resulting in Supernus stockholders owning approximately 43.5% …

Lantheus Holdings to Be Acquired for Initial $6.7 Billion

Lantheus Holdings is set to be acquired by Curium, a radiopharmaceutical company backed by CapVest Partners, for an initial $6.7 billion. Curium will pay $102.50 per share in cash, representing a 2.9% premium over Friday's closing price. This acquisition follows Lantheus's comprehensive evaluation of …

Curium Announces Definitive Agreement to Merge with Lantheus

Curium and Lantheus Holdings, Inc. have announced a definitive agreement for Curium to acquire Lantheus for up to $8.0 billion. The transaction involves a cash payment of $102.50 per share at closing, plus Contingent Value Rights of up to $12.00 per share tied to …

Curium to buy Bedford-based Lantheus in deal worth up to $8B

Curium is set to acquire Lantheus, a 70-year-old radiopharmaceutical company based in Massachusetts, for up to $8 billion. The acquisition highlights a significant transaction in the radiopharmaceutical field, though the future of Lantheus' Massachusetts workforce remains uncertain. The deal was reported by the Boston …

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

Akebia Therapeutics has initiated a Phase 2 basket trial to evaluate ebribafusp, a next-generation complement inhibitor, for rare kidney diseases such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial aims to assess the safety, efficacy, and pharmacokinetics of weekly subcutaneous dosing, focusing …

LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus potential additional contingent value rights. The firm is examining whether Lantheus and its board …

Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics

Supernus Pharmaceuticals (SUPN) reported $219.06 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 32.4%. EPS of $0.54 for the same period compares to $0.91 a year ago. The reported revenue represents a surprise of +6.84% over the Zacks …

Eton Pharmaceuticals (ETON) Files For Pediatric Label Expansion, Is The Stock Fully Priced?

Haleon (NYSE: HLN) details share count and voting rights update

Haleon plc has provided an update on its share capital and voting structure as of July 31, 2026. The company reported a total of 8,820,906,422 ordinary shares issued, with 11,879,800 of these held as treasury shares. Consequently, 8,809,026,622 ordinary shares carry voting rights, a …

Supernus jumps premarket on merger deal; GameStop drops

Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stocks attempted to extend their recovery following July's sharp …

BTIG Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40

BTIG has reiterated its Buy rating for BioAge Labs (BIOA.US) and maintained its target price at $40. This indicates a continued positive outlook from BTIG on the company's stock performance.

H.C. Wainwright reiterates Neurocrine Bio stock rating on pipeline progress By Investing.com

H.C. Wainwright has reaffirmed its Buy rating and $215.00 price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX), citing the company's strong pipeline progress and financial performance. The company reported significant revenue growth and provided updates on its clinical trials for osavampator and direclidine, which …

Lantheus Holdings to Merge With Curium US Holdings in Up to $8 Billion Transaction Closing in H1 2027

Lantheus Holdings is set to merge with Curium US Holdings in a transaction valued at up to $8 billion, which is expected to close in the first half of 2027. This acquisition will see Curium expanding its radiopharma capabilities by integrating Lantheus, a company …

BioXcel Therapeutics amends Oaktree-led credit agreement, defers loan payment to Aug. 31

BioXcel Therapeutics has amended its credit agreement with lenders led by Oaktree Fund Administration, deferring a loan payment of $9.02 million from July 31 to August 31, 2026. The company also saw its minimum liquidity covenant lowered to $6.25 million from $7.5 million. BioXcel …

HCM Stock Price and Chart — NASDAQ:HCM

This

Eton Gains on Acquiring Right to Baby Medicine

Eton Pharmaceuticals (NASDAQ: ETON) has acquired the U.S. commercialization rights to HEMANGEOL® oral solution, an Orphan Drug for infantile hemangioma, from Pierre Fabre Medicament Sas. This acquisition, combined with the recent approval of DESMODA™, brings Eton's commercial product portfolio to ten, reinforcing its focus …

At a glance: stocks gapping up premarket

[Wall Street New York City] aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-up moves before the bell on Monday. Stock index futures were higher on Monday as investors looked forward to a busy week of corporate earnings …

Indivior stock soars 9% on strong earnings beat and raised guidance

Indivior Pharmaceuticals Inc. (NASDAQ:INDV) saw its stock rise by 9.22% after reporting strong second-quarter results that exceeded analyst expectations. The company also raised its full-year 2026 revenue and adjusted EBITDA guidance, driven by record SUBLOCADE net revenue. This performance reflects strong operational execution and …

Did Strong Q2 Results and Higher 2026 Revenue Guidance Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?

Novo misses, AstraZeneca holds steady, Alvotech clears FDA – the Nordic Pulse | 2026:31

This article provides the Nordic Life Science Weekly Report for Week 31, 2026, offering key insights into the market, major events, financial impact, development and research, and a catalyst watch. It highlights that Novo Nordisk missed expectations, AstraZeneca remained stable, and Alvotech received FDA …

TherapeuticsMD, Inc. (29TA.SG) Stock Price, News, Quote & History

The article provides a snapshot of TherapeuticsMD, Inc. (29TA.SG) stock performance as of August 7, 2026. It highlights the stock's price, recent news, and historical data. Key performance metrics like Year-To-Date and 1-Year trailing total returns are compared against the S&P 500 index.